BeiGene
ONC
#733
Rank
HK$206.72 B
Marketcap
HK$1,779
Share price
-0.76%
Change (1 day)
73.47%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (ONC) - Total assets

Total assets on the balance sheet as of December 2024 : HK$45.94 Billion

According to BeiGene 's latest financial reports the company's total assets are HK$45.94 Billion. A companyโ€™s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.

BeiGene - Total assets on balance sheet (from 2014 to 2024)

Total assets by year

Year Total assets Change
2024-12-31HK$45.96 B1.38%
2023-12-31HK$45.33 B-9.04%
2022-12-31HK$49.84 B-25.11%
2021-12-31HK$66.55 B53.29%
2020-12-31HK$43.41 B245.78%
2019-12-31HK$12.55 B-28.72%
2018-12-31HK$17.61 B115.47%
2017-12-31HK$8.17 B159.81%
2016-12-31HK$3.14 B247.72%
2015-12-31HK$0.90 B117.6%
2014-12-31HK$0.41 B354.62%
2013-12-31HK$91.48 M

Total Assets for similar companies or competitors

Company Total assets differencediff. Country
HK$0.14 B-99.69%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$17.07 B-62.84%๐Ÿ‡บ๐Ÿ‡ธ USA